Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer

Abstract

Activation of kinases signalling pathways contributes to various malignant phenotypes in human cancers, including breast tumour. To examine the possible activation of these signalling molecules, we examined the phosphorylation status in 12 protein kinases and transcription factors in normal primary human mammary epithelial cells, telomerase-immortalised human breast epithelial cell line, and two breast cancer lines, MDA-MB-468 and MCF-7, using Kinexus phosphorylated protein screening assays. The phosphorylation of FAK, mTOR, p70S6K, and PDK-1 were elevated in both breast cancer cell lines, whereas the phosphorylation of AKT, EGFR, ErbB2/ Her2, PDGFR, Shc, and Stat3 were elevated in only one breast cancer line compared to normal primary mammary epithelial cells and telomerase-immortalised breast epithelial cells. The same findings were confirmed by Western blotting and by kinase assays. We further substantiated the phosphorylation status of these molecules in tissue microarray slides containing 89 invasive breast cancer tissues as well as six normal mammary tissues with immunohistochemistry staining using phospho-specific antibodies. Consistent findings were obtained as greater than 70% of invasive breast carcinomas expressed moderate to high levels of phosphorylated PDK-1, AKT, p70S6K, and EGFR. In sharp contrast, phosphorylation of the same proteins was nearly undetectable or was at low levels in normal mammary tissues under the same assay. Elevated phosphorylation of PDK-1, AKT, mTOR, p70S6K, S6, EGFR, and Stat3 were highly associated with invasive breast tumours (Po0.05). Taken together, our results suggest that activation of these kinase pathways by phosphorylation may in part account for molecular pathogenesis of human breast carcinoma. Particularly, moderate to high level of PDK-1 phosphorylation was found in 86% of high-grade metastasised breast tumours. This is the first report demonstrating phosphorylation of PDK-1 is frequently elevated in breast cancer with concomitantly increased phosphorylation of downstream kinases, including AKT, mTOR, p70S6K, S6, and Stat3. This finding thus suggested PDK-1 may promote oncogenesis in part through the activation of AKT and p70S6K and rationalised that PDK-1 as well as downstream components of PDK-1 signalling pathway may be promising therapeutic targets to treat breast cancer. Breast cancer remains to be a major cause of death in women worldwide, despite improvements in cancer prevention, early detection, treatment, and understanding the molecular pathogenesis. It hence demands an urgent need to unveil the exact mechanism of oncogenesis and tumour progression, which may prelude the development of new strategies for treatment. Breast carcinoma emerges through multistep processes progressing from hyperplasia to premalignant change, in situ carcinoma, invasion, and distal metastasis, in concomitant with gain of oncogenic activities and loss of tumour suppressor gene functions.Protein kinases have been implicated in playing crucial roles in regulating cell growth, met...

Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor

“…From a mechanistic perspective, these ER-independent proapoptotic mechanisms could be pharmacologically exploited by targeting PDK-1/Akt signaling to lower the apoptosis threshold in ER-negative breast cancer cells. This hypothesis is of clinical relevance in light of recent evidence that PDK-1/Akt signaling is frequently upregulated in breast cancers (6,23,24). The findings presented here provide the proof-of-principle of this hypothesis by showing the ability of the PDK-1/Akt signaling inhibitor OSU-03012 to sensitize MDA-MB-231 cells to the antiproliferative effects of tamoxifen.…”

Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors

“…This kinase regulates the efficiency of translation of certain mRNAs and also functions in a negative feedback loop to control Akt activity (Chiang and Abraham, 2005;Inoki et al, 2005;Martelli et al, 2007). Akt, mTOR and p70S6K activation have been associated with a more severe prognosis in breast and other cancers (Bose et al, 2002;Clark et al, 2002;DeGraffenried et al, 2004;Nagata et al, 2004;Lin et al, 2005;Tsutsui et al, 2005a, b;Klos et al, 2006;Tokunaga et al, 2006;Martelli et al, 2007). Targeting the PI3K/Akt/mTOR pathway may prove effective in various cancer therapies (Martelli et al, 2007).…”

PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound

“…PDK-1 can transform normal human cells and may be involved in invasion and metastasis process (Zeng et al, 2002;Xie et al, 2003Xie et al, , 2006. PDK-1 and its downstream target AKT are frequently phosphorylated and activated in multiple types of cancers (Cheng et al, 1992;Sun et al, 2001;Lin et al, 2005). Constitutive activation of PI3-K/PDK-1/AKT signalling mediates the survival signals and confers resistance to apoptosis induced by anticancer cytotoxic agents in human cancer cells (Page et al, 2000;Nesterov et al, 2001;Clark et al, 2002).…”